Impact of delayed treatment on exacerbations of multiple sclerosis among Puerto Rican patients.
Adverse impact of multiple sclerosis treatment delay
Multiple sclerosis comorbidities
Multiple sclerosis symptoms
Multiple sclerosis treatment
Puerto Rican multiple sclerosis patients
Puerto Rico health- care system
Journal
Surgical neurology international
ISSN: 2229-5097
Titre abrégé: Surg Neurol Int
Pays: United States
ID NLM: 101535836
Informations de publication
Date de publication:
2019
2019
Historique:
received:
24
07
2019
accepted:
26
08
2019
entrez:
27
11
2019
pubmed:
27
11
2019
medline:
27
11
2019
Statut:
epublish
Résumé
There are limited data on multiple sclerosis (MS) patients in underserved groups, including Puerto Rico. In this study, we analyzed the characteristic of MS symptoms and number of relapses in Puerto Rican patients. We then compare these characteristics with MS patients from the US. The number of MS relapses is highly correlated with the treatment onset and adherence. Patients in Puerto Rico have been experiencing lengthy treatment delay. We will discuss the possible causes of such delay and its impact on MS prognosis. This retrospective cohort study consisted of the evaluation of 325 medical records from MS patients attending the Caribbean Neurological Center from 2014 to 2019. We gathered symptoms and comorbidities data as binary objects. The treatment delay was calculated based on the mean value of days between diagnosis and treatment onset for these groups of patients. We found that on average, the treatment delay for MS patients in Puerto Rico (PR) to receive their medication was 120 days. The most common MS subtype was relapsing-remitting 72.8%, with a mean of 1.684 relapses per year. Initial symptoms were sensory 54%, visual 33.1%, motor 28.8%, coordination 23.2%, fatigue 9.7%, memory 7.3%, depression 6.5%, urinary 4.9%, gastrointestinal 2.4%, and sexual dysfunction 1.6%. The most common comorbidities were hypertension 18.4%, asthma 13.6%, and thyroid disease 12.8%. When we compared the comorbidities between the two populations, immune thrombocytopenia had the highest percent change with the value of almost 200% (0.001% of US patient vs. 0.8% of Puerto Rican MS patients). Patients from Puerto Rico had a 33% higher relapse rate compared to the one reported for MS patients in the US. This higher rate may be related to the long delay in receiving their medications. They also had a higher rate of complex comorbidities such as immune thrombocytopenia or thyroid disease. Our findings provide a proof of concept that delay in receiving medications can increase the number of relapses and complex comorbidities among MS patients.
Sections du résumé
BACKGROUND
BACKGROUND
There are limited data on multiple sclerosis (MS) patients in underserved groups, including Puerto Rico. In this study, we analyzed the characteristic of MS symptoms and number of relapses in Puerto Rican patients. We then compare these characteristics with MS patients from the US. The number of MS relapses is highly correlated with the treatment onset and adherence. Patients in Puerto Rico have been experiencing lengthy treatment delay. We will discuss the possible causes of such delay and its impact on MS prognosis.
METHODS
METHODS
This retrospective cohort study consisted of the evaluation of 325 medical records from MS patients attending the Caribbean Neurological Center from 2014 to 2019. We gathered symptoms and comorbidities data as binary objects. The treatment delay was calculated based on the mean value of days between diagnosis and treatment onset for these groups of patients.
RESULTS
RESULTS
We found that on average, the treatment delay for MS patients in Puerto Rico (PR) to receive their medication was 120 days. The most common MS subtype was relapsing-remitting 72.8%, with a mean of 1.684 relapses per year. Initial symptoms were sensory 54%, visual 33.1%, motor 28.8%, coordination 23.2%, fatigue 9.7%, memory 7.3%, depression 6.5%, urinary 4.9%, gastrointestinal 2.4%, and sexual dysfunction 1.6%. The most common comorbidities were hypertension 18.4%, asthma 13.6%, and thyroid disease 12.8%. When we compared the comorbidities between the two populations, immune thrombocytopenia had the highest percent change with the value of almost 200% (0.001% of US patient vs. 0.8% of Puerto Rican MS patients).
CONCLUSION
CONCLUSIONS
Patients from Puerto Rico had a 33% higher relapse rate compared to the one reported for MS patients in the US. This higher rate may be related to the long delay in receiving their medications. They also had a higher rate of complex comorbidities such as immune thrombocytopenia or thyroid disease. Our findings provide a proof of concept that delay in receiving medications can increase the number of relapses and complex comorbidities among MS patients.
Identifiants
pubmed: 31768280
doi: 10.25259/SNI_252_2019
pii: SNI-10-200
pmc: PMC6826276
doi:
Types de publication
Journal Article
Langues
eng
Pagination
200Informations de copyright
Copyright: © 2019 Surgical Neurology International.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Gait Posture. 2016 Sep;49:277-282
pubmed: 27474948
Neurology. 2006 Oct 10;67(7):1242-9
pubmed: 16914693
Mult Scler Relat Disord. 2017 Apr;13:87-92
pubmed: 28427709
Pain. 2013 May;154(5):632-642
pubmed: 23318126
J Med Econ. 2017 May;20(5):493-502
pubmed: 28035846
JAMA. 2006 Dec 20;296(23):2832-8
pubmed: 17179460
Acta Neurol Scand. 2011 Aug;124(2):109-14
pubmed: 20809902
Ethn Dis. 2010 Autumn;20(4):451-7
pubmed: 21305836
Mult Scler. 2008 Sep;14(8):1026-30
pubmed: 18632775
Mult Scler Relat Disord. 2014 Mar;3(2):227-36
pubmed: 25878010
Int Rev Psychiatry. 2010;22(1):14-21
pubmed: 20233111
Res Nurs Health. 2017 Apr;40(2):143-152
pubmed: 28165143
Contemp Clin Trials. 2014 Nov;39(2):288-93
pubmed: 25311447
Clin Neuropsychol. 2010 Oct;24(7):1131-45
pubmed: 20830649
Sociol Health Illn. 2015 Jul;37(6):904-19
pubmed: 25720591
Surg Neurol Int. 2018 Dec 03;9:242
pubmed: 30603227
J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1186-91
pubmed: 23595944
PLoS One. 2014 Nov 24;9(11):e113933
pubmed: 25419842
Bol Asoc Med P R. 2013;105(1):18-23
pubmed: 23767380
Neurology. 2010 Mar 30;74(13):1041-7
pubmed: 20350978
Mult Scler. 2008 Sep;14(8):1091-8
pubmed: 18728060
P R Health Sci J. 2015 Jun;34(2):83-8
pubmed: 26061058
Neuroepidemiology. 2017;48(1-2):55-60
pubmed: 28334724
Mult Scler. 2017 Nov;23(13):1757-1761
pubmed: 28080255
Arch Phys Med Rehabil. 2018 Oct;99(10):2022-2029
pubmed: 29698641
Mult Scler. 2015 Mar;21(3):332-41
pubmed: 25538150
J Neurol. 2008 Sep;255(9):1354-60
pubmed: 18677639
Neuroepidemiology. 2009;32(1):72-9
pubmed: 19001800
Acta Neurol Scand. 2011 Aug;124(2):135-41
pubmed: 20880264
Neuroepidemiology. 2017;49(3-4):106-112
pubmed: 29136613
Am J Manag Care. 2013 Nov;19(16 Suppl):s294-300
pubmed: 24494618
Mult Scler Relat Disord. 2018 Feb;20:43-47
pubmed: 29291483
Eur J Epidemiol. 2017 Oct;32(10):909-919
pubmed: 28597127
Arch Phys Med Rehabil. 2006 Sep;87(9):1274-9; quiz 1287
pubmed: 16935067
N Engl J Med. 2018 Jul 12;379(2):162-170
pubmed: 29809109
Mult Scler. 2015 Mar;21(3):263-81
pubmed: 25623244
BMC Neurol. 2017 Aug 7;17(1):151
pubmed: 28784102
Mult Scler. 2001 Oct;7(5):340-4
pubmed: 11724451
Genes Immun. 2009 Jan;10(1):11-4
pubmed: 18987646
PLoS One. 2016 Jul 13;11(7):e0159129
pubmed: 27411042
Neurology. 2016 Apr 12;86(15):1446-1453
pubmed: 26865523
Neuroepidemiology. 2011;36(2):85-90
pubmed: 21282965
Mult Scler. 2012 Sep;18(9):1310-9
pubmed: 22328682
Lancet. 1998 Nov 7;352(9139):1491-7
pubmed: 9820296
P R Health Sci J. 2012 Dec;31(4):213-9
pubmed: 23844469
Neurology. 2013 Mar 12;80(11):1018-24
pubmed: 23427319
J Neurol. 2005 Aug;252(8):892-6
pubmed: 15895310
Disabil Health J. 2010 Oct;3(4):262-70
pubmed: 21122795
MMWR Morb Mortal Wkly Rep. 2017 Mar 10;66(9):246-253
pubmed: 28278145
Lancet. 1982 Jan 9;1(8263):74-6
pubmed: 6119494
JAMA Neurol. 2014 Mar;71(3):306-14
pubmed: 24445558
Photochem Photobiol. 2007 Mar-Apr;83(2):459-63
pubmed: 17115796
Phys Med Rehabil Clin N Am. 2005 May;16(2):327-49
pubmed: 15893675
Open Forum Infect Dis. 2018 Dec 03;6(1):ofy325
pubmed: 30631791
Lancet Neurol. 2004 Feb;3(2):104-10
pubmed: 14747002
Nicotine Tob Res. 2018 Apr 2;20(5):589-595
pubmed: 28402456
Neurology. 2019 Mar 5;92(10):e1029-e1040
pubmed: 30770430
J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):196-203
pubmed: 27683916
Neurol Clin Pract. 2016 Apr;6(2):177-182
pubmed: 27104069
PLoS One. 2016 Feb 05;11(2):e0148573
pubmed: 26849357
J Epidemiol. 2017 May;27(5):235-241
pubmed: 28142047
Disabil Rehabil Assist Technol. 2017 Aug;12(6):641-646
pubmed: 27762151
Bol Asoc Med P R. 2012 Sep-Dec;104(4):4-9
pubmed: 23763216
BMC Public Health. 2018 Apr 12;18(1):491
pubmed: 29650018
Semin Neurol. 2016 Apr;36(2):103-14
pubmed: 27116717
Patient Prefer Adherence. 2010 Feb 04;4:1-9
pubmed: 20165593
Lancet. 2007 Aug 4;370(9585):389-97
pubmed: 17679016
Mult Scler. 2017 Feb;23(2):277-285
pubmed: 27230791
J Neurol. 2016 Jun;263(6):1053-65
pubmed: 26705122
Neurology. 1991 May;41(5):692-6
pubmed: 1823781
West J Med. 2000 Dec;173(6):398-402
pubmed: 11112758
Ann Am Thorac Soc. 2015 Dec;12(12):1760-3
pubmed: 26551268
Mult Scler Int. 2017;2017:8010912
pubmed: 29348937
J Neurol. 2018 May;265(5):1096-1101
pubmed: 29508133
Brain. 2003 Feb;126(Pt 2):433-7
pubmed: 12538409
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Mult Scler. 2005 Oct;11(5):602-9
pubmed: 16193900
J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):844-850
pubmed: 29618493
Mol Aspects Med. 2015 Apr;42:42-60
pubmed: 25579746
J Bone Miner Res. 2014 Nov;29(11):2520-6
pubmed: 24771492
Pain Med. 2012 Oct;13(10):1358-65
pubmed: 22925457
Patient Prefer Adherence. 2014 Dec 04;8:1653-64
pubmed: 25525341
Acta Neurol Scand. 2012 Mar;125(3):180-6
pubmed: 21615355
J Neurol Sci. 2015 Jan 15;348(1-2):126-31
pubmed: 25480016
Dermatology. 2013;227(3):250-4
pubmed: 24134867
N Engl J Med. 2000 Sep 28;343(13):898-904
pubmed: 11006365
Neuroepidemiology. 2006;26(1):1-3
pubmed: 16254448
Lancet Neurol. 2006 Nov;5(11):924-31
pubmed: 17052659
Neurology. 2009 Oct 27;73(17):1394-8
pubmed: 19858462